Sanofi Ends Lung Cancer Drug Study After Trial Failure
A logo at the Sanofi SA campus in the Gentilly district of Paris.
Photographer: Nathan Laine/BloombergThis article is for subscribers only.
Sanofi will stop developing an experimental lung cancer medicine after it failed to impress in a late-stage trial.
The French drugmaker is terminating the program for tusamitamab ravtansine, an antibody-based treatment that failed to outperform a chemotherapy in treating some patients with metastatic non-squamous non-small cell lung cancer.